MAP2K7 and metastatic colorectal cancer: In regards of the horizontal strategy, the dual targeted inhibition of MEK and PI3K pathway effectors promises to be a valid strategy to overcome resistance to MEK inhibitor therapy in metastatic colorectal cancer, which is characterized by a frequent perturbation of the MAPK and PI3K signaling axis (Temraz et al., 2015).